NASDAQ: GERN · Life Sciences · 3 alerts · CIK 886744
Share price
$0.9419Close, Nov 16
Market cap
$607M
Shares outstanding
644.24MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Geron Corp filings on SEC EDGAR ↗
Geron Corporation reported a net income of $1.35 million for the third quarter of 2026, a significant improvement from the $18.4 million net loss in the same period of 2025, driven by a 27% increase in product revenue to $60.1 million. Despite the quarterly profit, the company recorded a net loss of $19.0 million for the first nine months of 2026 as it continues to manage high operating expenses and inventory investments.
Geron Corporation reported third quarter 2026 financial results, highlighted by $60.1 million in RYTELO net product revenue, a 5% increase over the prior quarter. The company reiterated its full-year RYTELO revenue guidance at the mid-to-high end of $220-$240 million and initiated a gated commercial launch in Europe, with availability expected in Germany by year-end.
Term
Q3 2026
“Another quarter of strong RYTELO demand growth reinforces our confidence in the LR-MDS commercial opportunity and our ability to reach more second-line patients. Increased demand growth is being driven by the community practices which, in our view, indicates the potential for RYTELO to have a long growth runway in the U.S.”
Harout Semerjian, President and Chief Executive Officer of Geron
Geron Corporation is discontinuing its Phase 3 IMpactMF clinical trial of imetelstat in relapsed/refractory myelofibrosis based on a recommendation from an independent Data Monitoring Committee. The committee advised that the trial was unlikely to meet its primary endpoint of overall survival, although no new safety signals were observed.